Ritonavir-dependent fluconazole boosting of nelfinavir: A report of three cases [5]

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 483-485

  Garazzino, Silvia ^a   Tettoni, M ^a   Calcagno, A ^a   D'Avolio, A ^a   Bonora, S ^a   Di Perri, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Drug interactions; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; EFAVIRENZ; FLUCONAZOLE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; STAVUDINE;

ADULT; AREA UNDER THE CURVE; BINDING AFFINITY; CANDIDA; CASE REPORT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TRANSFORMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MEDICAL DECISION MAKING; THRUSH;

ADULT; ANTIFUNGAL AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; RITONAVIR;

EID: 33748061641     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl232     Document Type: Letter

References (8)

1. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7.
2. Boffito M, Maitland D, Samarasinghe Y et al. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin infect Dis 2005; 18: 1-7.
3. Peytavin G, Dominguez S, Lamotte C et al. Minimization of the triple reciprocal lopinavir/ritonavir/amprenavir (LPV/RTV/APV) interaction by low-dose fluconazole (FCZ) in experienced HIV-1-infected patients (Pts) in the Lopigen Prospective Study. In: Abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment Paris, 2003. Abstract 864. Antivir Ther 2003; 8 Suppl 1: S428.
4. Koks CH, Crommentuyn KM, Hoetelmans RM et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001; 51: 631-5.
5. Van Heeswijk R, Sabo JP, MacGregor TR et al. The effect of tipranavir/ ritonavir 500/200 mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volounteers. In: Abstracts of the Fifth International Workshop on Clinical Pharmacology in HIV Therapy, Rome, 2004. Abstract 20, poster 4.8.
6. Jackson KA, Rosenbaum SE, Kerr BM et al. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000; 44: 1832-7.
7. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32: 1462-7.
8. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005; 28: 1805-8.